Comprehensive analysis of PGIM India Healthcare Fund - Direct (IDCW) (45234) providing detailed insights into fund performance, portfolio holdings, risk metrics, expense ratios, and investment recommendations.
PGIM India Asset Managers Private Ltd
The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. However, there is no assurance that the investment objective of the scheme will be achieved. The Scheme does not guarantee/ indicate any returns.
A comprehensive at-a-glance view of key mutual fund health indicatorsHover or click any card to view detailed metrics
Good Returns
High Risk
Low Expense Ratio
Equity Focused
New Team
Below Average
Showing 1Y NAV history
Performance across different time periods
Fund shows mixed signals. Consider your investment timeline and risk tolerance.
Review detailed analysis and consider dollar-cost averaging through SIPs.
Fund shows mixed signals. Consider your investment timeline and risk tolerance.
Review detailed analysis and consider dollar-cost averaging through SIPs.
Recent performance momentum
Outperformance vs benchmark
Market exposure level
Fund management costs
Risk-adjusted returns
Fund manager experience
Assets under management
Historical performance consistency
This fund has underperformed its benchmark by 48.32% over the 3Y period.
See how your money can grow and compare with popular investment options
Disclaimer: Returns are illustrative and based on assumed rates. Mutual fund investments are subject to market risk. Please read scheme documents carefully.
| Company | Sector | % Assets |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | Pharmaceuticals | 12.57% |
| Divis Laboratories Ltd | Pharmaceuticals | 8.31% |
| Max Healthcare Institute Ltd | Healthcare | 7.72% |
| Dr Reddys Laboratories Ltd | Pharmaceuticals | 6.21% |
| Aster DM Healthcare Ltd | Healthcare | 5.48% |
| Mankind Pharma Ltd | Pharmaceuticals | 5.13% |
| Torrent Pharmaceuticals Ltd | Pharmaceuticals | 4.46% |
| Krishna Institute of Medical Sciences Ltd | Healthcare | 3.92% |
| Abbott India Ltd | Pharmaceuticals | 3.64% |
| Ajanta Pharma Ltd | Pharmaceuticals | 3.49% |
Compare against Sectoral / Thematic category average
This comparison shows how the fund performs relative to the Sectoral / Thematic category average. Positive values indicate outperformance, while negative values show underperformance.
Compare with similar funds in Sectoral / Thematic category
| Fund Name | NAV | 1M | 3M | 6M |
|---|---|---|---|---|
| Aditya Birla SL MNC Fund - Direct (G) | ₹1540.61 | 1.47% | 4.17% | 20.90% |
| Aditya Birla SL MNC Fund - (G) | ₹1383.22 | 1.41% | 3.98% | 20.48% |
| Nippon India Banking&Financial Services-Dir(G) | ₹662.94 | -1.32% | -2.23% | 13.57% |
| Nippon India Banking&Financial Services-Dir(Bonus) | ₹662.94 | -1.32% | -2.23% | 13.57% |
| Nippon India Banking&Financial Services (G) | ₹606.00 | -1.39% | -2.44% | 13.09% |
| Nippon India Banking&Financial Services (Bonus) | ₹606.00 | -1.39% | -2.44% | 13.09% |
| Nippon India Pharma Fund - Direct (G) | ₹574.98 | -0.43% | 2.59% | 13.30% |
| Nippon India Pharma Fund - Direct (Bonus) | ₹574.98 | -0.43% | 2.59% | 13.30% |
| Franklin India Technology Fund - Direct (G) | ₹565.29 | 2.73% | 3.31% | 7.85% |
| ICICI Pru FMCG Fund - Direct (G) | ₹542.41 | 1.69% | 3.11% | 13.18% |
A seasoned investment professional with over 1 years of experience in equity research and fund management. Known for consistent performance and a disciplined investment approach focused on quality growth stocks.